Results 41 to 50 of about 32,832 (202)
Paths of FGFR-driven tumorigenesis [PDF]
Cell Cycle, 2009 Fibroblast growth factor receptors (FGFRs) comprise a subfamily of receptor tyrosine kinases (RTKs) that are master regulators of a broad spectrum of cellular and developmental processes, including apoptosis, proliferation, migration and angiogenesis. Due to their broad impact, FGFRs and other RTKs are highly regulated and normally only basally active.
Victor D, Acevedo +2 more
openaire +2 more sources
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Cells, 2021 Increasing evidence indicates that success of targeted therapies in the treatment of cancer is context-dependent and is influenced by a complex crosstalk between signaling pathways and between cell types in the tumor.
Harriet R. Ferguson +2 more
doaj +1 more source
Targeting FGFR Signaling in Cancer [PDF]
Clinical Cancer Research, 2015 Abstract The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary conserved signaling cascade that regulates several basic biologic processes, including tissue development, angiogenesis, and tissue regeneration. Substantial evidence indicates that aberrant FGFR signaling is involved in the pathogenesis of cancer.
Mehdi, Touat +4 more
openaire +2 more sources
Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment
Biomedicines, 2023 In carcinogenesis of the gastrointestinal (GI) tract, the deregulation of fibroblast growth factor receptor (FGFR) signaling plays a critical role.
Margherita Ratti +7 more
doaj +1 more source
BMC Cancer, 2022 Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the development
Andrew J. Weickhardt +8 more
doaj +1 more source
Cancer Management and Research, 2021 Changlin Mao,1 Wei Dong,2 Jiaju Lu,3 Zhao Zhang,4 Hongliang Wu,5 Armin Ghavamian,1 Dongbin Bi,3 Pei Gao,1 Zhao Liu,5 Sentai Ding1,3 1Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong ...
Mao C +9 more
doaj
Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
International Journal of Retina and Vitreous, 2021 Background Pemigatinib is an inhibitor of the fibroblast growth factor receptor (FGFR), recently approved for the treatment of cholangiocarcinoma. FGFR retinopathy is a newly recognized entity, with only two other FGFR inhibitors reported to cause serous
Oleg Alekseev, Effy Ojuok, Scott Cousins
doaj +1 more source
MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells
Frontiers in Oncology, 2021 Deregulation of fibroblast growth factor receptors (FGFRs) signaling, as a result of FGFR amplification, chromosomal translocation, or mutations, is involved in both initiation and progression of a wide range of human cancers. Clinical data demonstrating
Kamila Kitowska +10 more
doaj +1 more source
FGFR-2, FGFR-2-IIIb and FGFR-2-IIIc mRNA expression in thyroid cancer progression.
, 2013 (A) Quantitative Real-Time PCR analysis of FGFR-2-IIIb mRNA expression in normal thyroid tissue, hyperplastic thyroid tissue, follicular adenoma and papillary carcinoma. Relative FGFR-2-IIIb mRNA levels are shown as fold value of the level of FGFR-2-IIIb
Giorgio Di Rocco (382578) +10 more
core +1 more source
Bilateral Subretinal Fluid Accumulation during Erdafitinib Therapy
TNOA Journal of Ophthalmic Science and ResearchFibroblast growth factor receptor (FGFR) plays a major role in maintaining retinal pigment epithelium cells. Drugs that inhibit the FGFR pathway block the activation of the mitogen-activated protein kinase pathway, leading to the synthesis of ...
Rajneesh Singh +3 more
doaj +1 more source